<DOC>
	<DOCNO>NCT00471991</DOCNO>
	<brief_summary>The aim monocenter , open-label , randomize study determine ovulation inhibitory effect combine oral contraceptive ( COC ) SH T04769G collect supplementary data regard ovulation inhibitory effect COC Valette® SH D00659AF ( 0.03 mg EE 2.0 mg DNG ) , apply two treatment cycle 60 healthy female volunteer , age 18-35 years.Combined oral contraceptive consist two component : estrogen progestin . The estrogen require regular cycle ; progestin ensure protection unwanted pregnancy . In sufficient dosage , progestins prevent ovulation . The investigational product oral contraceptive contains estrogen ethinylestradiol progestin dienogest active ingredient . 21 tablet take cycle follow 7-day tablet-free interval . Thus , whole cycle last 28 days.The market oral contraceptive Valette® contain ingredient ( ethinylestradiol dienogest ) high dose . One half volunteer ( 30 volunteer ) receive product . Efficacy safety already confirm numerous clinical studies.Another 30 volunteer receive investigational product . The dose reduction assume negative impact tolerance.The study aim show whether reduced dosage sufficient contraception.Course study : The study consist 4 cycle ( one cycle treatment , follow two treatment cycle one post-treatment cycle ) result approx . 16 week study participation . The post-treatment cycle aim observe return normal function ovary . Volunteers come visit every 2 4 day whole study period.Visit 1The investigator explain study detail volunteer give ample time opportunity ask question . If question answer volunteer decide participation study . If decides take part , give write consent Informed Consent Form.Afterwards , pregnancy test perform , complete medical , surgical medication history record physical gynaecological examination perform . Transvaginal ultrasonography do smear mouth uterus take precaution cancer.Blood ( 10 ml ) drawn determine routine safety lab , heart rate blood pressure measure height weight recorded.Volunteers provide diary filled daily basis whole study period ( bleed record , intake study medication , performance pregnancy test ) .During whole study non-hormonal method contraception use ( condom plus spermicide ; diaphragm spermicide ) . During cycle study treatment , function ovary study transvaginal ultrasonography determination hormonal parameter blood sample . The mouth uterus inspect visit cervical smear investigate . Visits perform every 4 days.If ovulation confirm , volunteer randomize one treatment groups.Volunteers receive investigational product undergo blood sample give day cycle determine baseline hormonal status ( fast condition ) .A home pregnancy test do volunteer intake study medication . Only case pregnancy exclude , intake study medication start.Treatment cycle : During cycle , visit perform every 3 day determine ovarian activity ( transvaginal ultrasonography , blood sampling , inspection mouth uterus cervical smear investigation ) . Adverse event record diary entry control investigator.Volunteers receive investigational product undergo series blood sample 2nd treatment cycle evaluate pharmacokinetic ( liberation , absorption , distribution , metabolization excretion ) new oral contraceptive.Post-treatment cycle : Non-hormonal contraceptive method also use post-treatment cycle . It start immediately 2nd treatment cycle , i.e. , 8th day last tablet intake end start next menstrual bleeding . Visits perform every 4 day determine return ovarian activity transvaginal ultrasound measure blood sample hormone determination . After end next menstrual bleeding , final Visit include physical gynaecological examination perform . Options contraceptive method discuss investigator .</brief_summary>
	<brief_title>Valette ( Combined Oral Contraceptive SH T04769G SH D00659AF ) Low Ovulation Inhibition</brief_title>
	<detailed_description>The trial sponsor Bayer Schering Pharma AG , Germany .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Healthy female volunteer , age 18 35 year ( smoker 30 year ) Willingness apply nonhormonal method contraception course study ( e.g. , condom spermicide , diaphragm spermicide ) Confirmation ovulation cycle treatment Normal routine blood value Contraindications use oral contraceptive Pregnancy , lactation Simultaneous participation another clinical study Considerable overweight</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Oral contraceptive</keyword>
	<keyword>ovulation inhibitory effect</keyword>
</DOC>